{"log_id": 8546569866410091727, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.011913, "average": 0.941751, "min": 0.599792}, "location": {"width": 337, "top": 147, "height": 42, "left": 167}, "words": "大于3.0mg/dl时,采用常用量的14"}, {"probability": {"variance": 9e-06, "average": 0.998414, "min": 0.983611}, "location": {"width": 841, "top": 182, "height": 54, "left": 168}, "words": "肾功能不全患者:由于多柔比星由肝脏代谢和经胆汁排泄,故使用本品时剂量不需要调整"}, {"probability": {"variance": 0, "average": 0.972766, "min": 0.972766}, "location": {"width": 26, "top": 186, "height": 25, "left": 1165}, "words": "监"}, {"probability": {"variance": 9e-06, "average": 0.998698, "min": 0.983447}, "location": {"width": 629, "top": 236, "height": 49, "left": 169}, "words": "脾切除患者:目前尚无本品用于脾切除患者的经验,故不推荐使用"}, {"probability": {"variance": 6e-06, "average": 0.99863, "min": 0.993001}, "location": {"width": 118, "top": 309, "height": 28, "left": 128}, "words": "【不良反应】"}, {"probability": {"variance": 6e-06, "average": 0.998287, "min": 0.99139}, "location": {"width": 543, "top": 336, "height": 45, "left": 171}, "words": "以下来自国外上市的盐酸多柔比星脂质体的临床文献资料"}, {"probability": {"variance": 2e-06, "average": 0.999168, "min": 0.992171}, "location": {"width": 899, "top": 376, "height": 55, "left": 173}, "words": "对 aids-ks患者进行的临床开放和对照研究显示,与盐酸多柔比星脂质体相关的最常见的不良反"}, {"probability": {"variance": 2e-06, "average": 0.998887, "min": 0.994995}, "location": {"width": 348, "top": 440, "height": 43, "left": 132}, "words": "应是骨髓抑制,几乎近一半患者发生"}, {"probability": {"variance": 1e-06, "average": 0.999412, "min": 0.995272}, "location": {"width": 897, "top": 475, "height": 55, "left": 177}, "words": "白细胞减少是患者最常见的不良反应,也可见贫血和血小板减少。这些反应一般在治疗早期便可"}, {"probability": {"variance": 1.2e-05, "average": 0.998627, "min": 0.978393}, "location": {"width": 942, "top": 525, "height": 56, "left": 135}, "words": "见,但仅是暂时性的。临床试验中很少有因严重骨髓抑制而停药的事件发生。在出现血液学毒性反应"}, {"probability": {"variance": 2e-06, "average": 0.998865, "min": 0.994228}, "location": {"width": 502, "top": 587, "height": 44, "left": 134}, "words": "时,应按“出现血液毒性的剂量调整”方法进行处理"}, {"probability": {"variance": 2.6e-05, "average": 0.998217, "min": 0.967725}, "location": {"width": 898, "top": 624, "height": 56, "left": 179}, "words": "在临床研究使用盐酸多柔比星脂质体过程中,出现的较常见的有临床意义的实验室检查异常(≥"}, {"probability": {"variance": 2.7e-05, "average": 0.998177, "min": 0.964448}, "location": {"width": 936, "top": 674, "height": 55, "left": 144}, "words": "5%),还包括碱性磷酸酶升高以及天门冬氨酸氨基转移酶和胆红素升高,但这些检查异常被认为与基"}, {"probability": {"variance": 1.4e-05, "average": 0.997959, "min": 0.981569}, "location": {"width": 939, "top": 722, "height": 58, "left": 139}, "words": "础疾病有关,而与盐酸多柔比星脂质体无关。根据报道,在使用盐酸多柔比星脂质体的过程中,血红"}, {"probability": {"variance": 1.1e-05, "average": 0.998195, "min": 0.983928}, "location": {"width": 941, "top": 773, "height": 56, "left": 141}, "words": "蛋白和血小板减少的发生率较低(<5%),白细胞减少导致的脓毒血症更为少见(<1%)。上述某些"}, {"probability": {"variance": 0.005763, "average": 0.982124, "min": 0.553666}, "location": {"width": 686, "top": 830, "height": 48, "left": 141}, "words": "检测指标异常的产生可能与HIⅣV感染有关,而非盐酸多柔比星脂质体造成"}, {"probability": {"variance": 1.2e-05, "average": 0.99834, "min": 0.979539}, "location": {"width": 894, "top": 872, "height": 54, "left": 183}, "words": "其他发生率较高(≥5%)的不良反应有:恶心,无力,脱发,发热,腹泻,与滴注有关的急性"}, {"probability": {"variance": 0.001565, "average": 0.982836, "min": 0.886049}, "location": {"width": 156, "top": 944, "height": 32, "left": 144}, "words": "反应和口腔炎等"}, {"probability": {"variance": 0, "average": 0.954138, "min": 0.954138}, "location": {"width": 165, "top": 900, "height": 77, "left": 983}, "words": "河"}, {"probability": {"variance": 0.004421, "average": 0.980403, "min": 0.602181}, "location": {"width": 971, "top": 956, "height": 74, "left": 186}, "words": "滴注反应主要有潮红,气短,面部水肿,头痛,寒颤,背痛,胸部和喉部收窄感,低血压。在多"}, {"probability": {"variance": 0.000555, "average": 0.991776, "min": 0.846698}, "location": {"width": 1009, "top": 1013, "height": 66, "left": 146}, "words": "数情况下,不良反应发生在第一个疗程。采用某种对症处理,暂停滴注或减缓滴注速率后经过几个小一"}, {"probability": {"variance": 1e-06, "average": 0.999025, "min": 0.997869}, "location": {"width": 198, "top": 1091, "height": 31, "left": 145}, "words": "时即可消除这些反应"}, {"probability": {"variance": 1e-06, "average": 0.998999, "min": 0.99472}, "location": {"width": 902, "top": 1118, "height": 55, "left": 189}, "words": "据报道,连续滴注常规盐酸多柔比星的患者可见口腔炎,接受盐酸多柔比星脂质体的患者亦时有"}, {"probability": {"variance": 1.8e-05, "average": 0.99819, "min": 0.978623}, "location": {"width": 944, "top": 1167, "height": 57, "left": 148}, "words": "报道。这并不影响患者完成治疗。一般无需调整剂量,除非口腔炎影响患者的进食,此时可延长给药"}, {"probability": {"variance": 9e-06, "average": 0.997209, "min": 0.991844}, "location": {"width": 109, "top": 1242, "height": 27, "left": 150}, "words": "间期或减量"}, {"probability": {"variance": 0.00826, "average": 0.969323, "min": 0.558879}, "location": {"width": 903, "top": 1262, "height": 63, "left": 193}, "words": "盐酸多柔比星脂质体临床研究中常发生呼吸系统不良反应(≥5%)这可能与ADS患者的机会性"}, {"probability": {"variance": 0.00648, "average": 0.975633, "min": 0.538565}, "location": {"width": 944, "top": 1316, "height": 57, "left": 151}, "words": "感染有关。AIDS-KS患者使用本品后可见机会性感染,在HIV引起的免疫缺陷患者中常见发生。在临"}, {"probability": {"variance": 3.9e-05, "average": 0.997775, "min": 0.959343}, "location": {"width": 946, "top": 1364, "height": 61, "left": 152}, "words": "床研究中,最常见的机会性感染是念珠菌病,巨细胞病毒感染,单纯疱疹,肺囊虫肺炎及单纯鸟"}, {"probability": {"variance": 2e-06, "average": 0.998572, "min": 0.99573}, "location": {"width": 133, "top": 1440, "height": 30, "left": 154}, "words": "分支杆菌感染"}, {"probability": {"variance": 8e-06, "average": 0.998674, "min": 0.983177}, "location": {"width": 878, "top": 1466, "height": 54, "left": 197}, "words": "其他不很常见的不良反应(<5%)有手掌足底红斑性感觉迟钝,口腔念珠菌病,恶心,呕吐"}, {"probability": {"variance": 3e-06, "average": 0.998884, "min": 0.99176}, "location": {"width": 933, "top": 1516, "height": 55, "left": 155}, "words": "体重下降,皮疹,口腔溃疡,呼吸困难,腹痛,过敏反应包括过敏症,血管扩张,头晕,厌食,舌炎"}, {"probability": {"variance": 5e-06, "average": 0.998344, "min": 0.993413}, "location": {"width": 372, "top": 1580, "height": 39, "left": 157}, "words": "便秘,感觉异常,视网膜炎和意识模糊"}], "language": 3}